P ulmonary hypertension (PHT) is a disease characterized by raised pulmonary vascular resistance. It has a poor prognosis typically resulting in progressive right ventricular failure and death. The incidence of arrhythmias in patients with PHT is high. 1-3 All forms of supraventricular tachycardia are more common in PHT with studies suggesting an incidence of ≈3% per year and a prevalence of supraventricular arrhythmia of ≈12%. 3 Atrial flutter, atrial fibrillation, and atrioventricular (AV) nodal reentrant tachycardia are common. 3, 4 There is evidence of AV node dysfunction in PHT with a 14% incidence of first-degree heart block, a mean PR interval of 180±50 ms (mean±SD), and 2% of patients requiring a pacemaker for high-degree heart block on initial screening of PHT patients. 1 This can be compared with an incidence of first-degree heart block of 2.1% and mean PR interval of 160±22 ms (mean±SD) for men and 153±22 ms (mean±SD) for women in the general population. 5 Sleep apnea causes PHT 6 and is associated with heart block (heart block during sleep has been described in ≤10% of patients with obstructive sleep apnea). 7 Despite the evidence of a high burden of arrhythmias in patients with PHT, including dysfunction of the AV node, there are limited experimental data looking at the mechanisms of arrhythmia
generation, and the available data only concern arrhythmogenic mechanisms in the ventricle. 8 There are several animal models of PHT, but the monocrotaline model is the best characterized and most widely used. 9 Two studies using in vivo monitoring have demonstrated severe AV node dysfunction with heart block causing death in ≈38% of monocrotaline-injected rats with PHT. 10, 11 In this study, the monocrotaline-injected rat was chosen to study the mechanisms underlying AV node dysfunction in PHT (further validation of the monocrotaline-injected rat model is given in the Data Supplement). We show that the dysfunction is associated with widespread remodeling of the ion channel transcriptome.
Methods
Two-hundred gram male Wistar rats received an intraperitoneal injection of monocrotaline (60 mg/kg) or volume-matched 0.9% saline (3 mL/kg). Rats were weighed, and their clinical condition assessed twice weekly in the first 18 days and daily thereafter. Rats were assessed using echocardiography and ECG recording on day 0 immediately before injection, day 21, and immediately before termination. M-mode recordings were taken in the parasternal short-axis view allowing recording of left ventricle anterior and posterior wall thickness and the internal diameter of the left ventricle in both systole and diastole. Right ventricle wall thickness was measured from M-mode recordings in the parasternal long-axis view. Continuous wave Doppler recordings through the pulmonary artery were used to assess the pulmonary velocity profile. Monocrotaline-injected rats were euthanized by stunning and cervical dislocation on day 28 or earlier if there was evidence of clinical deterioration (reduced movement, increased respiratory rate, piloerection, and weight loss of >10 g over 2 days). A saline-injected rat was euthanized within 24 hours of euthanize of a monocrotalineinjected rat. Heart and lungs were excised and weighed. Telemetric recordings of ECGs from conscious and unrestrained male Wistar rats were made as previously described by Benoist et al. 12 The functioning of the AV node was measured in the Langendorff-perfused heart; the heart was mounted on a Langendorff column and retrogradely perfused with oxygenated Tyrode solution at a temperature of 36.5°C. Extracellular electrodes were used to record a pseudo-ECG. RR, PR and QT intervals, and QRS duration were measured. Pacing protocols were performed to measure atrial and ventricular effective refractory periods (ERPs), AV node refractory periods, and Wenckebach cycle length. Functioning of the AV node was also measured in the isolated AV node; a preparation was placed in a perfusion bath with oxygenated Tyrode solution at 36.5°C. Extracellular electrodes were used to record signals in the atrium and at the His bundle. Pacing protocols were performed to measure AV node refractory periods and Wenckebach cycle length. From the isolated AV node, intracellular actions potentials were also recorded with sharp microelectrodes.
Tissue was microdissected from different regions of the AV node; the AV node was sectioned at 50 μm in a cryostat. Sections 300 μm apart were stained with Masson trichrome and immunolabeled for HCN4 and Cx43 to identify AV node tissues. Guided by this, AV node tissues were dissected with a sharp needle from remaining sections (hematoxylin and eosin stained). Total RNA was extracted using the MirVana kit, residual genomic DNA removed using TurboDNAse, RNA in each sample measured using the Qubit system, RNA reverse transcribed to produce cDNA using SuperScript VILO Mastermix with random hexamers, cDNA preamplified, and expression of different cD-NAs corresponding to different mRNAs quantified using the TaqMan low density array card system (Life Technologies). Expression was normalized to the abundance of a pair of housekeeper genes, B2M and PKG1, selected from 16 potential housekeeper genes as the most stable.
The limma statistical package as implemented by RealTime Statminer software (Integromics) was used to compare mRNA expression in the control and monocrotaline-injected rats and compare mRNA expression in the different parts of the AV node. Multiple comparisons in large bodies of data, such as in microarray data analysis, pose statistical challenges. 13, 14 Typically, a correction is made when making multiple tests to avoid false-positive results (type I error), 13, 14 but reducing the type I error increases the chance of false-negative results (type II error). 13, 14 In relation to large data sets, Rothman 14 has argued that a policy of not making corrections for multiple tests is preferable. For comparison of mRNA expression in the control and monocrotaline-injected rats, the uncorrected P value is given in Table III in the Data Supplement. Even without the argument from Rothman, 14 this can be justified because each comparison is independent of the others (the conclusions of this study do not depend on a group of differences being significant). Nevertheless, false discovery rate (FDR)-corrected P values are also given in Table III in the Data Supplement; multiple test corrections of the classical type are not commonly used in the analysis of microarray data and instead the FDR has become a standard for multiple tests correction. 13 In reporting both uncorrected and FDR-corrected P values from the limma test, we follow the example of earlier studies. 15, 16 In the figures presenting quantitative PCR data, however, for simplicity, the asterisks relate only to the FDR-corrected P value; cases in which the FDRcorrected P value is <0.2 (ie, 20%) are highlighted with asterisks. An FDR of 20% (as we have used previously 16 ) is permissive and means that ≈20% of the 77 changes highlighted by asterisks, that is, ≈15, are false positives. However, precise uncorrected and FDR-corrected P values are reported in Table III in the Data Supplement, and the reader can make their own choice of what is acceptable. Rothman 14 states that scientists should not be so reluctant to explore leads that may turn out to be wrong that they penalize themselves by missing possibly important findings. For comparison of mRNA expression in the different parts of the AV node, we report FDR-corrected P values of <0.2 (using lower case letters) and <0.05 (using upper case letters) in the figures presenting quantitative PCR data, corresponding to FDRs of 20% and 5%. In this case, expression in various tissues is being compared, and a multiple test correction is appropriate and we do not report uncorrected P values.
The potential consequences of the changes in transcripts were explored using a biophysically detailed 1-dimensional (1D) model (52.5 mm in length) consisting of segments of atrium (15 mm), AV node (12.5 mm), Purkinje fiber (20 mm), and ventricle (10 mm), each represented by a well-established model of the corresponding action potential. To simulate the functional effects of PHT, the conductance of each ionic current was scaled based on the change in the corresponding mRNA. The 1D cable equation was solved using the forward-time central-space scheme with a space step of 0.1 mm and time step of 0.005 ms. Finally, expression of protein was investigated using immunohistochemistry.
Expanded methods are shown in the Data Supplement.
Results

PHT and Right-Sided Heart Failure
There was no significant difference in the body weight of control (saline injected) and monocrotaline-injected rats on the day of
WHAT IS KNOWN
• Pulmonary hypertension (PHT) has a poor prognosis typically resulting in progressive right ventricular failure and death.
• Patients with PHT have a high burden of arrhythmias, including heart bock.
WHAT THE STUDY ADDS
• PHT results in a remodeling of the atrioventricular (AV) node, and this is the likely cause of the AV node dysfunction and heart block in this disease.
• The most important element of the remodeling is a derangement of the ion channel transcriptome of the AV node. Table 1 ). During the following 3 weeks, the monocrotaline-injected rats gained significantly less weight such that they weighed 12% less than the control rats by the day of termination (Table 1 ). Despite the lower body weight, the monocrotaline-injected rats also had a 23% increase in heart weight and an 88% increase in lung weight compared with the control group ( Table 1 ). The heart:body weight and lung:body weight ratios were significantly greater in the monocrotaline-injected rats on the day of termination suggestive of congestive heart failure (Table 1) . Previous studies of the monocrotaline model using echocardiography have demonstrated a characteristic change in the pulmonary artery velocity profile from the typical rounded shape to a spike and dome morphology with a reduced pulmonary artery acceleration time and an increased pulmonary artery deceleration as pulmonary artery pressure increases. 17, 18 In this study, pulmonary artery acceleration time and pulmonary artery deceleration were used as surrogate measures of pulmonary artery pressure. On the day of termination, echocardiography demonstrated a reduced pulmonary artery acceleration time and increased pulmonary artery deceleration in the monocrotalineinjected rats ( Figure 1B ; Table 1 ). This is evidence of PHT, and monocrotaline-injected rats will now be referred to as PHT rats.
There was evidence of right-sided heart failure in the PHT rats; there was right ventricular dilatation (increased right ventricular internal dimension) and hypertrophy (increased right ventricular diastolic wall thickness) and a 36% reduction in right ventricular fractional shortening ( Figure 1A ; Table 1 ). In contrast, in the left ventricle, there was no evidence of hypertrophy, and there was a reduced left ventricular internal diameter in the PHT rats; this was presumably the result of the raised right ventricular pressure pushing the ventricular septum into the left ventricle ( Figure 1A ; Table 1 ). On the day of termination, the ECG measured in vivo in the anesthetized rat showed a 98% increase in the QT interval, a 90% increase in the corrected QT interval, and a 9% increase in the RR interval (equivalent to 9% decrease in heart rate) in the PHT rats (Table 1) ; these changes are typical of heart failure. 19 Although no changes were seen in the PR interval (Table 1) , the PR interval is determined by the position of the leading pacemaker site in the right atrium and the conduction velocity of the AV node. We have previously reported similar changes in the ECG measured in vivo in the conscious rat using telemetry. 12 In the United Kingdom, the Animal (Scientific Procedures) Act 1986 requires that monocrotaline-injected rats are euthanized before they reach end-stage heart failure. However, 1 conscious freely moving rat implanted with a telemetry system died naturally 28 days after injection with monocrotaline, and the ECG recording showed that it died of heart block ( Figure 1C ). This is consistent with earlier reports. 10, 11 
Evidence From In Vitro Experiments of AV Node Dysfunction
It is possible that the AV node is supported in vivo by neurohumoral influences, and, therefore, experiments were conducted on isolated heart preparations. First, experiments were conducted on the isolated Langendorff-perfused heart from 10 control and 11 PHT rats. Consistent with the in vivo measurements, there were a 141% increase in the QT interval, a 138% increase in corrected QT interval, and a 144% increase in the ventricular ERP in the PHT rats (Table 2 ). There was also a 24% increase in the atrial ERP, but this was not significant ( Table 2 ). Once again there was no change in the PR interval, but there was evidence of AV node dysfunction in the PHT rats; Figure 2A shows typical AV node conduction curves from control and PHT rats; there was a significant increase in both the AV node ERP (AVERP) and AV node functional refractory period (AVFRP). The Wenckebach cycle length was increased (but not significantly) in the PHT rats. Although this increase was not significant, linear regression showed the Wenckebach cycle length to be significantly correlated with both the AVERP and AVFRP, and this suggests that PHT does tend to prolong the Wenckebach cycle length ( Figure 2B ). Experiments were also conducted on an isolated right atrial preparation containing the AV node from 10 control and 11 PHT rats. Electrograms were recorded from above the His bundle, and examples are shown in Figure 2C ; both atrial and His bundle electrograms were recorded at the recording site. There was normal AV node conduction in the control rat, but complete heart block in the PHT rat with dissociation of the atrial and His bundle electrograms ( Figure 2C ). There was a 50% incidence of complete heart block in the PHT rats (6 of 12 PHT rats) compared with 0% in the control group (0 of 10 control rats); the difference is statistically significant (Fisher exact test; P=0.015; Table 2 ). In the remaining 6 PHT rat preparations in which AV node conduction persisted, there were increases in the AH interval (interval between atrial and His bundle electrograms), the Wenckebach cycle length, and the AVERP and AVFRP (at 2 drive train cycle lengths), although the increases did not reach significance (Table 2 ). Finally, using sharp microelectrodes, intracellular action potentials were recorded from isolated right atrial preparations from a further 5 control and 6 PHT rats because this technique allows the wellknown electric heterogeneity of the AV node 20 to be explored (Figure 3 ). The preparations were paced from the region of the sinus node at 5 Hz. Normal AV node conduction was observed in 4 out of the 5 control preparations, whereas abnormal conduction was observed in 5 out of the 6 PHT preparations ( Table  I in the Data Supplement). In PHT preparations, Figure 3B shows an example of complete conduction block in the compact node (the action potentials show no correspondence to the stimulation artifacts and are spontaneous), and Figure 3C shows a case of decremental conduction in the penetrating bundle. Taken together, these data show evidence of AV node dysfunction in the PHT rat.
Remodeling of AV Node
To understand the mechanisms underlying AV node dysfunction in PHT, the expression of ion channels, connexins, intracellular Ca 2+ -handling proteins, ion pumps, and exchangers and autonomic receptors was measured at the mRNA level using quantitative PCR from 8 control and 8 PHT rats. Tissue was microdissected from 4 different regions of the AV node (transitional tissue, inferior nodal extension, compact node, and penetrating bundle- There are many significant differences in expression between different regions of the AV node but for brevity are not discussed here. There are many significant differences in expression (generally downregulation) caused by PHT, and these are considered below. 
Downregulation of Inward Current Carrying Ion Channels
In the AV node, inward current carrying ion channels play a role in diastolic depolarization, setting excitability and the upstroke and plateau of the action potential. HCN channels play an important role in pacemaking. HCN4 was the most abundant isoform, and there was a trend of downregulation (significant in 2 regions) in the AV node in PHT (Figure 4 ). Na v 1.1 is a subsidiary Na + channel involved in pacemaking and the action potential upstroke, and again there was a trend of downregulation (significant in 1 region) in the AV node in PHT (Figure 4 ). However, Na v 1.5 and Na v β1 are responsible for the principal Na + channel in the heart, and they were unaffected ( Figure 4 ). Na v 1.8 is responsible for the late Na + current 22 ; its expression in the AV node was unaffected in PHT, but interestingly its expression level was high in the penetrating bundle ( Figure III CLC-3 is a volume-regulated Cl − channel, 23 and it was 
Downregulation of Outward Current Carrying Ion Channels
Voltage-gated K + channels play an important role in action potential repolarization. The voltage-gated K + channel subunits responsible for the transient outward K + current (K v 1.4, K v 4.2, K v 4.3, and KChIP2) and delayed rectifier K + current (K v 1.2, K v 1.5, K v 2.1, ERG1, K v LQT1, and minK) tended to be downregulated (significantly in some cases) in the AV node in PHT ( Figure 5 ; Figure III in the Data Supplement). There were 3 significant decreases in inward rectifier K + channels in the AV node in PHT: K ir 3.1 (subunit of acetylcholine-activated K + channel) in the transitional tissue, K ir 3.4 (another subunit of acetylcholine-activated K + channel) in the inferior nodal extension, and K ir 6.2 (subunit of ATP-sensitive K + channel) in the transitional tissue (Figure 6) . The twin-pore K + channel, TWIK1, was significantly downregulated in the inferior nodal extension in the AV node in PHT ( Figure 6 ). The downregulation of the K + channels is expected to prolong the AV node action potential, although such an effect would be countered by the downregulation of inward current carrying ion channels.
Downregulation of Intracellular Ca 2+ -Handling Molecules
Intracellular Ca 2+ plays an important role in pacemaking and conduction in the AV node. 24, 25 Expression of many intracellular Ca 2+ -handling molecules was affected in PHT. There tended to be a downregulation of NCX1 (Na + -Ca 2+ exchanger) in the AV node in PHT, but this was not significant (Figure 7 ). There was a tendency for RyR2 (the Ca 2+ release channel of the sarcoplasmic reticulum) to be downregulated in most tissues in PHT, and it was significantly downregulated in the inferior nodal extension (Figure 7) . Although expression of SERCA2 in the AV node was not affected in PHT, 2 regulators of SERCA2 (phospholamban and sarcolipin) were significantly downregulated in much of the AV node (Figure 7) . Two other Ca 2+ -handling molecules, calsequestrin 2 and PMCA1, were unaffected (Figure 7 ; Figure III in the Data Supplement). The downregulation of RyR2 could potentially slow AV node conduction.
Downregulation of Other Transcripts
In PHT, there was a trend of downregulation of the α2and α3-subunits of the Na + -K + pump throughout the AV node (significantly in some cases; Figure V in the Data Supplement).
However, the α1and β1-subunits were unchanged ( Figure  V in the Data Supplement). The Na + -H + exchanger was significantly upregulated in the inferior nodal extension in PHT ( Figure III in the Data Supplement). Connexins are responsible for electric coupling between myocytes and, therefore, are an important determinant of conduction velocity of the action potential. No changes were seen in Cx40, Cx43, and Cx45 in any of the nodal tissues (Figure 7) . However, Cx30.2 has been suggested to play a key role in nodal tissues, 26 and it was significantly downregulated in both the transitional tissue and inferior nodal extension in PHT (Figure 7) . The AV node is controlled by the autonomic nervous system. Although there were no changes in the M2 muscarinic and A1 adenosine receptors in the AV node in PHT, there were changes in adrenergic receptors; there was a significant downregulation in the α1a/1c adrenergic receptor in the inferior nodal extension, and importantly there was a significant downregulation of the β1-receptor (the most important adrenergic receptor) in the inferior nodal extension ( Figure VI in the Data Supplement). There were no significant changes in 2 other adrenergic receptors (α1b and β2; Figure VI in the Data Supplement). The downregulation of the β1 adrenergic receptor could negatively impact AV node conduction.
Remodeling Predicts Heart Block
The significant changes in transcripts in the AV node in PHT in this study are summarized in Tables II and III in the Data  Supplement. Biophysically detailed action potential models have been used to predict possible changes in electric activity based on changes in ion channel transcripts; ionic conductances are scaled depending on changes in mRNA (in the Data Supplement). This should be viewed as a form of bioinformatics. On the basis of a biophysically detailed 1D model of the conduction pathway from the atrium through the AV node and Purkinje fibers to the ventricle, 27 Figure 8 shows the predicted effects of PHT-induced ion channel remodeling; the assumed changes in ionic conductances (based on expression of corresponding mRNAs) are shown in Table XI in the Data Supplement. In control conditions, the action potential is predicted to conduct from the atrium to the ventricle ( Figure 8A) , and the conduction velocity ( Figure 8B ) and action potential waveform ( Figure 8C ) in the different tissues are as expected. However, in PHT, conduction is predicted to fail in the compact node (heart block; Figure 8 ) consistent with Figures 1 through 3 .
Of the changes in ion channels in PHT, the computer modeling predicts that the downregulation of the L-type Ca 2+ channels, Ca v 1.2 and Ca v 1.3, is the most important. The expected downregulation of I Ca,L in the N region alone is sufficient to cause heart block (data not shown).
Discussion
This study is the first to demonstrate widespread downregulation of the ion channel transcriptome in the AV node in response to a disease process. Previously, AV node disease has been commonly attributed to idiopathic fibrosis and sclerosis. 28 However, there are other recent data pointing to the importance of ion channels in normal AV conduction. A genomewide association study has demonstrated several loci that are associated with a prolonged PR interval, including genes for ion channels and developmental genes known to be important for the patterning of ion channels during embryogenesis. 29 There is also a recognition that several disease-causing ion channel mutations that have been characterized as causing Brugada syndrome and long QT syndrome are also associated with conduction system disturbances and heart block. 19 In addition to these findings in patients, gene knockout studies in mice have pointed to the importance of several ion channels, including voltage-dependent Ca 2+ channels 30 and HCN4 31 in maintaining normal AV conduction.
Dysfunction and Remodeling of AV Node in PHT
There was evidence of dysfunction of the AV node in the PHT rats; in the Langendorff-perfused heart, there was evidence of an increase in the AVERP, AVFRP, and Wenckebach cycle length, and, in the isolated AV node, there was a 50% incidence of complete heart block ( Figure 2 ). In 1 case, in which a PHT rat died with a telemetry system fitted, it died of heart block ( Figure 1C ), and this is consistent with earlier telemetric studies 10, 11 ; for example, Chi et al 11 reported that ≈38% of PHT (monocrotaline injected) rats die of heart block. There was a widespread downregulation in the ion channel transcriptome in the AV node in PHT (Tables II and III in the Data Supplement) . AV node conduction will be potentially slowed by the downregulation of many of the transcripts, and computer modeling confirmed that if the changes in mRNA are translated into changes in function, they will result in heart block (Figure 8 ). The potential role played by the downregulation of some transcripts will be briefly discussed.
Primary Role for Ca 2+ Channels
The upstroke and conduction of the action potential of the AV node is known to be dependent on L-type Ca 2+ channels. For example, knockout of either Ca v 1.2 and Ca v 1.3 has been reported to slow or block AV node conduction. 32, 33 A downregulation of Ca v 1.2 and Ca v 1.3 was observed in the AV node in PHT (Figure 4) , and the computer modeling predicts that the expected decrease in L-type Ca 2+ current alone is sufficient to cause heart block. We suggest that this is the primary cause of AV node dysfunction in PHT.
The T-type Ca 2+ channels, Ca v 3.1 and Ca v 3.2, also tended to decrease (Figure 4 ; Figure IV in the Data Supplement), and knockout of Ca v 3.1 at least has been shown to slow AV node conduction. 30 RyR2 was significantly downregulated in the AV node in PHT (Figure 7) . RyR2 is an important part of the Ca 2+ clock. The Ca 2+ clock and the membrane clock (the principal component of which is the funny current, I f ) controls pacemaking in the sinus and AV nodes. 24 However, there is also evidence that they control AV node conduction; Saeed et al 25 have shown that incapacitating RyR2 and the Ca 2+ clock by application of ryanodine slows AV node conduction. The Ca 2+ clock could control AV node conduction by affecting excitability, and, therefore, the downregulation of RyR2 in PHT may be important. Further components of the Ca 2+ clock tended to be downregulated in the AV node in PHT (Figure 7) , markedly in the case of phospholamban and sarcolipin; the consequences of these changes for AV node conduction are unknown.
Role for Downregulation of HCN4?
Downregulation of the HCN4 channel in the AV node was observed in PHT ( Figure 4 ; Figure VIII in the Data Supplement). HCN channels and I f (inward current during diastole that is responsible for phase 4 depolarization) have mainly been considered in relation to sinus node pacemaking. Indeed, an I f blocking drug, ivabradine, is used clinically to reduce sinus rate. Initial studies on a small number of patients demonstrated no effects on the AV node, and, therefore, subsequent larger studies have not investigated the effects of ivabradine on the AV node. 34 However, there are several recent studies that suggest that I f may play a significant role in AV node conduction. This study has demonstrated high levels of HCN4 in the AV node (Figure 4 ). There is also functional evidence that I f plays a role in AV node conduction; although ivabradine was not shown to have an effect on the human AV node, another I f blocking agent, zatebradine, has been shown to increase the AH interval, AVERP, and Wenckebach cycle length in humans. 35 Dronedarone has also been shown to slow the ventricular response to atrial fibrillation in dogs with the mechanism thought to be specific to I f blockade within the AV node slowing conduction and not a direct effect of I f blockade on the atrium. 36 Inducible cardiac-specific knockout of HCN4 in mice is lethal because of the development of complete heart block. 31 Saeed et al 25 have shown that in young rats I f block significantly prolongs the AH interval, AVERP, and Wenckebach cycle length. Downregulation of I f could slow AV node conduction by decreasing excitability of the cell. 37
Role for Other Factors?
A downregulation of various K + channels was observed in the AV node in PHT ( Figures 5 and 6 ). This is not surprising because in the ventricles a downregulation of K + channels has been shown in many different disease models, including PHT. 38 In the ventricles, the downregulation leads to a prolongation of the action potential. 38 In this study, it has not been highlighted, but many K + channels were downregulated in both the atrial and ventricular working myocardium Figure III in the Data Supplement), and the functional experiments demonstrated an increased ventricular ERP and suggested an increased atrial ERP, which is consistent with an increase in action potential duration. The downregulation of K + channels in the AV node could explain the observed increase in AVERP, AVFRP, and Wenckebach cycle length in PHT (Figure 2 ). In the transitional tissue at least, the computer (Figure 8 ). Regan et al 39 observed that selective pharmacological block of ERG (I K,r ) and K v LQT1 (I K,s ) both cause a prolonged AH interval and AVERP in rats. Although ERG and K v LQT1 were unaffected by PHT ( Figure 5 ), this demonstrates that K + channels are able to affect AV node conduction and refractoriness. Recently, Mesirca et al 40 reported that ablation of the acetylcholine-activated K + current (carried by K ir 3.1 and K ir 3.4) relieves the heart block in Ca v 1.3 knockout mice. In PHT, K ir 3.1 and K ir 3.4 tended to be downregulated in PHT, and this could be a compensatory mechanism. Changes in K + channels could potentially alter the membrane potential during diastole, and this would have indirect consequences, for example, for the Na + current. The only connexin that was significantly affected within the nodal tissue was Cx30.2, which was downregulated (Figure 7) . However, paradoxically, knockout of low conductance Cx30.2 leads to an increased conduction velocity across the AV node. 41
Cardiac Sympatholysis
Activation of the sympathetic nervous system and an increase in plasma norepinephrine levels are features of heart failure. 42 In keeping with this, Leineweber et al 43 showed that, in the monocrotaline-injected rat, plasma norepinephrine levels are markedly increased. The activation of the sympathetic nervous system can support the failing heart (although it can also be detrimental to the heart and cause hypertrophy for example). 42 In this study, whereas AV node function was generally normal in vivo (Table 1) , AV node function was worse in the Langendorff-perfused heart (AVERP and AVFRP were significantly longer; Table 2 ), and it was worse again in the isolated right atrial preparation (when conduction block was frequently observed; Figures 2 and 3; Table 2 ; Table I in the Data Supplement). This is consistent with the failing AV node in vivo being supported by the activation of the sympathetic nervous system.
In heart failure, the elevated norepinephrine levels are known to result in downregulation of β-receptors as a result of desensitization. 42 In the monocrotaline-injected rat, Leineweber et al 43 showed that there is a downregulation of β-receptors at the protein level and a diminished responsiveness to β-stimulation. The data from this study are consistent with this. In the rat, of the β1and β2-receptors, the β1-receptor is the dominant isoform, 43 and the same was true in this study at the mRNA level ( Figure VI in the Data Supplement). In this study, there tended to be a downregulation of β-receptors in the PHT rats (although the downregulation was only significant in some regions; Figure  VI in the Data Supplement). Interestingly, in this study, there was also a downregulation of α-receptors at the mRNA level in some regions ( Figure VI in the Data Supplement); Leineweber et al 43 also reported a downregulation. In a pilot experiment, sympathetic nerve fibers in the AV node were immunolabeled using an antibody to neurofilament 150 44 ; dense innervation was observed, but there was no marked change in PHT ( Figure VII in the Data Supplement). The consequences of these changes can only be speculated on. The downregulation of β-receptors in PHT could contribute to failure of the AV node in vivo (because activation of the sympathetic nervous system would no longer be able to support the failing AV node).
Clinical Implications
Heart block is a common condition in both PHT and the general population and is the indication for over half of implanted pacemakers. 45 AV node disease has typically been attributed to fibrosis, but this study shows that this is not necessarily the case. This study shows that in PHT it is more likely to be the result of remodeling of the ion channel transcriptome. In this respect, the AV node is no different from the rest of the heart; in heart disease, there is a well-known remodeling of the ion channel transcriptome in the sinus node and working myocardium. Recognition of the causes of AV node disease is the first step to developing new treatments.
Further discussion of the findings can be found in the Data Supplement.
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